The Companion Animal Vaccines Market Size was valued at USD 3.39 billion in 2023 and is expected to reach USD 5.64 billion by 2032 and grow at a CAGR of 5.83% over the forecast period 2024-2032. This report contains a detailed study of trends in the companion animal vaccine market, with a focus on drivers of growth. Growing pet ownership, more stringent immunization requirements, and increasing awareness of zoonotic disease drive vaccine demand. Veterinary infrastructure in the form of a robust network of clinics and mobile pet care services increases access, while FDA and USDA regulation guarantees vaccine safety and compliance. Research developments, including recombinant and DNA-based vaccines, enhance immunization tactics and increase market growth.
The U.S. Companion Animal Vaccines Market grew at a CAGR of 5.17% over the forecast period 2024-2032. In the United States, expenditure on healthcare for companion animal vaccines is increasingly growing, with private veterinary practice and owners propelling noteworthy out-of-pocket spending, indicative of increased prioritization of the health of pets.
Drivers
Rising Pet Ownership and Advancements in Veterinary Medicine
The companion animal vaccines market is growing with rising pet ownership and improvements in veterinary medicine. The COVID-19 pandemic had a massive impact on pet adoption levels, with many millions of households bringing home new pets. As of 2023, almost 66% of U.S. households have at least one pet, fueling greater demand for preventive health, including vaccination. Furthermore, knowledge of zoonotic diseases, including rabies and leptospirosis, has reinforced vaccine uptake, as both veterinarians and pet owners value disease prevention. Veterinary practice has also been enhanced by advances in recombinant and DNA vaccines, providing improved protection with reduced side effects. These advances have resulted in increased immunization coverage, providing improved disease control in companion animals. In addition, the emergence of mobile veterinary clinics and internet-based pet pharmacies has made vaccines more accessible. Furthermore, combination vaccines, which offer protection against several diseases in one injection, have gained popularity, making them more convenient for pet owners. Government campaigns encouraging responsible pet ownership and disease prevention have also helped to promote vaccine uptake. As pet owners treat pets as members of their families, increasing expenditure on preventive care from veterinarians continues to grow, and vaccination becomes an inherent aspect of pet care and a major growth driver for the market.
Restraints
The rising cost of veterinary care is a major restraint in the companion animal vaccines market, making routine vaccinations less accessible for some pet owners.
In the United States, veterinary service costs have risen by around 60% over the last ten years, due to shortages of labor, inflation, and escalating drug prices. The UK has also experienced a hike in veterinary expenses of more than 50% since 2015, rendering routine pet care even more costly. A major reason for this trend is the acquisition of veterinary clinics by private equity companies and large corporations, which has resulted in lower competition and increased service charges. Veterinary shortages have also made the situation worse, with fewer experts to give vaccines, increasing the cost of consultations. These economic barriers may deter pet owners from maintaining annual vaccinations, creating gaps in immunization coverage and enhancing the risk of disease outbreaks. In addition, supply chain interruptions, especially in vaccine manufacturing and distribution, have resulted in increased manufacturing costs, further driving prices up. Although pet insurance penetration has grown, coverage usually does not include routine vaccinations, so many owners end up paying out of pocket. These increasing expenses may restrict vaccine uptake, particularly in poorer households, curbing total market growth.
Opportunities
Advancements in vaccine technology present significant opportunities for the companion animal vaccines market.
One of the most promising is mRNA-based vaccines, which have transformed human medicine and are currently under development for veterinary use. Moderna, for instance, is investing in mRNA vaccines for animal disease, which may offer quicker and more effective protection against new pathogens. In the same way, vector-based and DNA vaccines provide enhanced safety profiles, minimizing the potential for adverse events in pets. Another significant development is oral and intranasal vaccines, which obviate injections and enhance pet compliance. Alternative vaccine forms increase ease for animals and ease of use for veterinarians. AI-based research has also speeded up vaccine development, cutting the time it takes for new products to come to market. Firms are also developing thermostable vaccines, which do not need to be stored in the cold, thus simplifying distribution and reducing costs. Furthermore, tailored vaccine formulations are being investigated to offer more specific protection according to a pet's risk factors. With more funding for animal health research and biotechnology, future vaccines will be expected to improve disease prevention, enhance pet welfare, and fuel market growth.
Challenges
Regulatory scrutiny and market consolidation present significant challenges to the companion animal vaccines industry.
The United States Federal Trade Commission (FTC) and the United Kingdom's Competition and Markets Authority (CMA) are probing consolidation in veterinary practice since about 30% of the U.S. veterinary practices are currently controlled by large conglomerates, and specialty clinics hit a 75% corporate share. This consolidation has been on account of growing concern regarding greater cost, decreasing competition, and access to economical treatment. Furthermore, the regulatory approval process for veterinary vaccines is strict, and this contributes to the difficulty. The European Medicines Agency (EMA) and the U.S. Department of Agriculture (USDA) demand extensive safety and efficacy trials, resulting in lengthy development periods and high costs before the entry of new vaccines into the market. Country-specific regulatory differences further complicate the approval and sale of vaccines around the world. Public skepticism of vaccinations, fueled by misinformation and fear of vaccine safety, is another challenge. Some owners are resistant to vaccinating their pets out of fear of side effects, even though scientific data support vaccine benefits. Removing these regulatory and market barriers is necessary to assure vaccine access, affordability, and ongoing innovation in the companion animal vaccine market.
By Technology
Live Attenuated Vaccines continued to hold a dominant market share with 39.8%. These employ a weakened version of the pathogen to trigger an effective immune response, nearly replicating natural infection. Their ability to produce long-term immunity with low doses has established them as a staple in veterinary immunization programs. The capacity of live attenuated vaccines to induce both humoral and cellular immunity is a factor in their popularity among veterinarians and pet owners. Storage, handling, and reversion to virulence considerations, however, require strict quality control. Despite these issues, their established efficacy and cost-benefit ratio have cemented their stronghold on the companion animal vaccine market.
Recombinant Vaccines are the fastest-growing segment in the market for companion animal vaccines. Recombinant Vaccines are designed by placing certain genes of the pathogen into a harmless vector, and that creates specific antigens that stimulate an immune response without the introduction of the actual pathogen. The accuracy of recombinant technology improves safety profiles through the elimination of risk factors with live pathogens, which is especially useful in immunocompromised animals. Genetic engineering advancements have enabled the creation of recombinant vaccines with the ability to target multiple diseases at once, making them more appealing in overall veterinary medicine. The enhanced focus on biosafety, in addition to the demand for efficient and targeted immunization, has driven the incorporation of recombinant vaccines and made them the fastest-growing area in 2023.
By Animal Type
Canine Vaccines remained a dominant segment of the companion animal vaccine market in 2023. Dogs, as some of the most popularly kept pets in the world, have influenced the demand for vaccines against rabies, distemper, parvovirus, and adenovirus. Improved human-animal bonds and greater awareness regarding zoonotic diseases have promoted greater vaccination of canines. Public health programs and compulsory vaccination legislation across much of the world have also served to enhance the significance of immunizing dogs. The presence of combination vaccines that offer protection against multiple pathogens in a single shot has also helped to ensure the continued dominance of the canine vaccine market.
Feline Vaccines have grown at an accelerated rate in recent years. The increased popularity of cats as pets, particularly in urban areas, has increased attention on feline health and preventive medicine. Vaccines for feline-specific conditions like leukemia virus, calicivirus, and herpesvirus have gained increased usage. Promotional campaigns to educate pet owners about the necessity of regular veterinary check-ups and vaccinations for both indoor and outdoor cats have been a factor. Moreover, the development of vaccines that minimize adverse reactions has also increased the attractiveness of feline vaccinations among pet owners and veterinarians alike, reinforcing their position as the fastest-growing category in the companion animal vaccine market.
North America dominated the market for global companion veterinary vaccines at 48.5% in 2023. Its well-established regulatory structures and the location of major vaccine companies enable consistent flows of product introductions from a pipeline of new products. Also, well-established vaccination patterns among veterinary practices and large budgets for procurement with significant buyers like veterinary hospitals are guaranteeing demand stability. It dominates vaccine classes in treating prime diseases like rabies and in growing therapeutic areas in canines and felines.
Asia Pacific is the market's fastest-growing region. Increasing pet ownership in China and India, spurred by rising prosperity and cultural trends favoring companion animals, fuels vaccine demand. The region's massive livestock base among Southeast Asian countries offers significant volume opportunity. The establishment of developing regulatory frameworks and an increase in local production capacities, in many cases through alliances and foreign investment, supports competitive pricing and enhanced supply security. Countries like Indonesia and Thailand have become regional export centers, supplying vaccines across the Asia Pacific and even internationally.
Elanco – Duramune series, Nobivac Canine 1-DAPPv
Boehringer Ingelheim International GmbH – Duramune series, Recombitek series
Intervet Inc. – Nobivac series
Zoetis Services LLC – Vanguard series, Felocell series
Bioveta, a.s. – Biocan series, Biofel series
Heska Corporation – UltraNasal series, DentaShield
Virbac – Canigen series, Feligen series
Hester Biosciences Limited – Hester canine vaccines
Vetoquinol India Animal Health Pvt Ltd – Vetrimoxin LA, Clamoxyl LA
Phibro Animal Health Corporation – MJPRRS, Trovac
HIPRA – Hiprabovis series, Hipradog series
Merck Sharp & Dohme Corp. – Nobivac series
Biovet Private Ltd – Biovac series
Ceva – Cevac series, Vectormune series
In Feb 2025, Medgene, a Brookings, SD-based animal health company, partnered with Elanco Animal Health to support the U.S. dairy industry and accelerate H5N1 vaccine availability. Their H5N1 vaccine for dairy cattle is in the final stages of USDA review for conditional approval, addressing significant losses in infected herds.
In June 2024, Merck Animal Health received USDA approval for NOBIVAC NXT Canine Flu H3N2, the first RNA-particle technology vaccine for canine influenza. This marks a significant advancement in veterinary vaccines, offering enhanced protection against the H3N2 strain.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.39 billion |
| Market Size by 2032 | USD 5.64 billion |
| CAGR | CAGR of 5.83% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology [Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Technologies] • By Animal Type [Dogs, Cats, Other Animal Types] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Elanco, Boehringer Ingelheim International GmbH, Intervet Inc., Zoetis Services LLC, Bioveta a.s., Heska Corporation, Virbac, Hester Biosciences Limited, Vetoquinol India Animal Health Pvt Ltd, Phibro Animal Health Corporation, HIPRA, Merck Sharp & Dohme Corp., Biovet Private Ltd, Ceva. |
Ans: The Companion Animal Vaccines market is anticipated to grow at a CAGR of 5.83% from 2024 to 2032.
Ans: The market is expected to reach USD 5.64 billion by 2032, increasing from USD 3.39 billion in 2023.
Ans: The companion animal vaccines market is growing with rising pet ownership and improvements in veterinary medicine.
Ans: The rising cost of veterinary care is a major restraint in the companion animal vaccines market, making routine vaccinations less accessible for some pet owners.
Ans: North America dominated the Companion Animal Vaccines market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Vaccination Trends (2023), by Region
5.2 Veterinary Infrastructure & Accessibility
5.3 Regulatory & Policy Trends Affecting the Market
5.4 Impact of Pet Ownership Trends on Vaccine Demand
5.5 Research & Development Trends in Companion Animal Vaccines
5.6 Healthcare Spending on Companion Animal Vaccines, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Companion Animal Vaccines Market Segmentation, by Technology
7.1 Chapter Overview
7.2 Live Attenuated Vaccines
7.2.1 Live Attenuated Vaccines Market Trends Analysis (2020-2032)
7.2.2 Live Attenuated Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Inactivated Vaccines
7.3.1 Inactivated Vaccines Market Trends Analysis (2020-2032)
7.3.2 Inactivated Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Toxoid Vaccines
7.4.1 Toxoid Vaccines Market Trends Analysis (2020-2032)
7.4.2 Toxoid Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Recombinant Vaccines
7.5.1 Recombinant Vaccines Market Trends Analysis (2020-2032)
7.5.2 Recombinant Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Other Technologies
7.6.1 Other Technologies Market Trends Analysis (2020-2032)
7.6.2 Other Technologies Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Companion Animal Vaccines Market Segmentation, by Animal Type
7.1 Chapter Overview
8.2 Dogs
8.2.1 Dogs Market Trends Analysis (2020-2032)
8.2.2 Dogs Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Cats
8.3.1 Cats Market Trends Analysis (2020-2032)
8.3.2 Cats Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Other Animal Types
8.4.1 Other Animal Types Market Trends Analysis (2020-2032)
8.4.2 Other Animal Types Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.4 North America Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.5.2 USA Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.6.2 Canada Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.7.2 Mexico Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.5.2 Poland Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.6.2 Romania Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.4 Western Europe Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.5.2 Germany Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.6.2 France Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.7.2 UK Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.8.2 Italy Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.9.2 Spain Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.12.2 Austria Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.4 Asia Pacific Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 China Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 India Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 Japan Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.6.2 South Korea Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.7.2 Vietnam Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.8.2 Singapore Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.9.2 Australia Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.4 Middle East Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.5.2 UAE Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.4 Africa Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Companion Animal Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.4 Latin America Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.5.2 Brazil Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.6.2 Argentina Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.7.2 Colombia Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Companion Animal Vaccines Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Companion Animal Vaccines Market Estimates and Forecasts, by Animal Type (2020-2032) (USD Billion)
10. Company Profiles
10.1 Elanco
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 Boehringer Ingelheim International GmbH
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Intervet Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Zoetis Services LLC
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Bioveta, a.s.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Heska Corporation
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Hester Biosciences Limited
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Vetoquinol India Animal Health Pvt Ltd
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Phibro Animal Health Corporation
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Merck Sharp & Dohme Corp.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Technology
Live Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Other Technologies
By Animal Type
Dogs
Cats
Other Animal Types
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Immunotherapy Drugs Market was valued at USD 246.00 billion in 2023 and is expected to reach USD 829.78 billion by 2032, growing at a CAGR of 14.49% over the forecast period 2024-2032.
The Patient Portal Market Size was valued at USD 3.35 billion in 2023 and is expected to reach USD 16.71 billion by 2032 and grow at a CAGR of 19.55% over the forecast period 2024-2032.
The Healthcare Market Size was valued at USD 21,222.5 Billion in 2023, and is expected to reach USD 44,760.73 Billion by 2032, and grow at a CAGR of 9.07% over the forecast period 2024-2032.
The Medical Terminology Software Market size was valued at USD 1.20 billion in 2023 and is expected to reach USD 4.95 billion by 2032 and grow at a CAGR of 17.09%.
The mRNA Sequencing Market size was USD 3.6 billion in 2023 and is expected to reach USD 7.19 billion by 2032 and grow at a CAGR of 8.0% from 2024-2032.
The Radiation Oncology Treatment Planning Software Market size was estimated at USD 2.18 billion in 2023 and is expected to reach USD 4.75 billion by 2032 at a CAGR of 9.04% during the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
